Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy

Fig. 5

Flow cytometry analysis of PD-1 and PD-L1 expression on immune cell subsets of BC patients. Percentage of PD-1 and PD-L1 expression on intratumoral myeloid cells (A) and B cells (B), NK (C), and NKT (D) cells are displayed. Data are given as mean ± SD (no significant differences were detected by Tukey’s multiple comparisons test). Red symbols represent Luminal B breast cancer patients with HER2 over-expression

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us